Scholars Central

Review articlePublished 2021

Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression

Authors: Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein

Systematic Reviews in Pharmacy

Volume 12 · Issue 3 · Pages 821–828

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

ROS-1 protein is a transmembrane protein with a tyrosine kinase activity act as a growth or differentiation factor can derived cell proliferation acting as a proto-oncogen. It is expressed in the kidney and gastrointestinal tract and, in rare cases, in several other organs as well. Genetic rearrangements of ROS1 have been found in non-small cell lung cancer (NSCLC) and in other tumors as well like gastric carcinoma, ovarian carcinoma and others. This protein became of clinical interest because of the era of tyrosin kinase inhibitors role in treating cancer like crizotinib which have been approved for NSCLC with ROS1 alterations. In this study we studied the immunohistochemical expression of ROS 1in mammary carcinoma in correlation with Hormonal receptor status (ER and PR) and Her2Neu expression. Paraffin blocks of thirty cases of mammary ductal carcinoma were selelcted and studied by immunohistochemical staining for ER, PR, Her2Neu and ROS 1. Then the findings were analyzed statistically Thirty-three percent of studied cases showed expression of ROS 1 which was assessed by stained cell proportion and cell staining intensity. Neither stained cell proportion nor the staining intensity of ER and PR showed significant statistical correlation with ROS 1 expression . However a significant correlation was noted between ROS 1 expression and Her2Neu expression as 70% of ROS 1 positive cases were also positive for Her2Neu. This suggest a negative prognostic role of this protein in mammary carcinoma. The finding of this relatively significant number of ROS 1 positive cases in mammary carcinoma can open the way for more understanding of mammary carcinoma pathogenesis and can open the way for the use of certain tyrosine kinase inhibitors in the most common type of female cancer. How to Cite this Article Pubmed Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. SRP. 2021; 12(1): 832-839. doi:10.31838/srp.2021.1.117 Web Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. http://www.sysrevpharm.org/?mno=45472 [Access: March 29, 2021]. doi:10.31838/srp.2021.1.117 AMA (American Medical Association) Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. SRP. 2021; 12(1): 832-839. doi:10.31838/srp.2021.1.117 Vancouver/ICMJE Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. SRP. (2021), [cited March 29, 2021]; 12(1): 832-839. doi:10.31838/srp.2021.1.117 Harvard Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein (2021) Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. SRP, 12 (1), 832-839. doi:10.31838/srp.2021.1.117 Turabian Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. 2021. Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. Systematic Reviews in Pharmacy, 12 (1), 832-839. doi:10.31838/srp.2021.1.117 Chicago Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. "Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression." Systematic Reviews in Pharmacy 12 (2021), 832-839. doi:10.31838/srp.2021.1.117 MLA (The Modern Language Association) Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein. "Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression." Systematic Reviews in Pharmacy 12.1 (2021), 832-839. Print. doi:10.31838/srp.2021.1.117 APA (American Psychological Association) Style Ameer Dh. Hameedi, Hassanien Gh. Hussein, Israa A. Hussein (2021) Immunohistochemical Expression Of ROS-1 In Mammary Ductal Carcinoma In Correlation With Hormonal Receptor Status And Her2Neu Expression. Systematic Reviews in Pharmacy, 12 (1), 832-839. doi:10.31838/srp.2021.1.117

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Systematic Reviews in Pharmacy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalSystematic Reviews in Pharmacy
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ameer Dh. Hameedi”
  • BylineArticles whose byline prints “Hassanien Gh. Hussein”
  • BylineArticles whose byline prints “Israa A. Hussein”